GlassScriptPhysician profile
Adam T Kafka
NPI 1699709220
$1,544.69
in general payments reported to CMS, 2019-2025
29 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $106 · 2021: $52.13 · 2022: $298 · 2023: $325 · 2024: $227 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.09 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $248.13 | 2019-2025 | Dysport |
| Coloplast Corp | $150.70 | 2022-2025 | Speedicath |
| Merz Pharmaceuticals, LLC | $129.56 | 2023-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $108.97 | 2020-2022 | |
| Allergan, INC. | $72.85 | 2019 | |
| Dynasplint Systems INC. | $50.73 | 2025 | Dynasplint |
| Medtronic USA, INC. | $46.90 | 2019 | |
| Grt US Holding, INC. | $43.74 | 2021-2022 | |
| Janssen Biotech, INC. | $38.09 | 2022-2023 | Imbruvica |
| Merz North America, INC. | $32.74 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $32.12 | 2023-2024 | Gemtesa |
| Amneal Pharmaceuticals LLC | $28.88 | 2022 | |
| Avanir Pharmaceuticals, INC. | $26.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $23.03 | 2023 | Keytruda |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.87 | 2021 | |
| Acadia Pharmaceuticals INC | $21.93 | 2023 | Daybue |
| Baxter Healthcare | $20.86 | 2022 | |
| Incyte Corporation | $20.03 | 2023 | Jakafi |
| Axsome Therapeutics, INC. | $19.73 | 2022 | |
| Lifeward, INC. | $19.40 | 2025 | |
| Metacel Pharmaceuticals LLC | $18.25 | 2022 | |
| Seagen INC. | $18.04 | 2023 | Adcetris |
| Daiichi Sankyo INC. | $17.90 | 2024 | Enhertu |
| Lilly USA, LLC | $16.46 | 2023 | Retevmo, Jaypirca, Verzenio |
| Eisai INC. | $15.88 | 2022 | |
| Piramal Critical Care | $14.83 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.63 | 2023 | Precisetumor |
| Jazz Pharmaceuticals INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kafka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.